Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
3 July 2017
07:00 BST
ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT
WITH GRÜNENTHAL FOR MIGRAINE TREATMENT
ZOMIG
AstraZeneca
announced today that it has completed the previously-announced
agreement with Grünenthal
for the global rights to Zomig (zolmitriptan) outside
Japan. Zomig is indicated
for the acute treatment of
migraines and cluster headaches, an area of medicine outside
AstraZeneca's strategic focus.
The net
consideration from the upfront payment received from
Grünenthal will be reported as Other Operating Income in the
Company's financial statements in the second quarter of 2017. Under
the terms of the agreement, AstraZeneca will also receive
additional future milestone payments and will continue
to manufacture and supply the medicine to Grünenthal
during a transition period.
About
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular &
Metabolic Diseases and
Respiratory. The Company also is selectively active in the areas of
autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please
visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media Relations
|
|
|
|
Esra Erkal-Paler
|
UK/Global
|
+44 203 749 5638
|
|
Karen Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Jacob Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele Meixell
|
US
|
+1 302 885 2677
|
|
Investor Relations
|
|
|
|
Thomas Kudsk Larsen
|
|
+44 203 749 5712
|
|
Craig Marks
|
Finance, Fixed Income, M&A
|
+44 7881 615 764
|
|
Henry Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Mitchell Chan
|
Oncology
|
+1 240 477 3771
|
|
Lindsey Trickett
|
Cardiovascular & Metabolic Diseases
|
+1 240 543 7970
|
|
Nick Stone
|
Respiratory
|
+44 203 749 5716
|
|
Christer Gruvris
|
Autoimmunity, Neuroscience & Infection
|
+44 203 749 5711
|
|
US toll free
|
|
+1 866 381 7277
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
|
Date:
03 July 2017
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|